Ranolazine
Brand: Ranexa (US/EU) / Ranozex (IN) / Ranolaz (BD)
Antianginal
Late sodium-current inhibitor
Pharmacokinetics
| Half-life | 7 hours |
| Tmax | 2 h |
| Bioavailability | 35 % (approx) |
| Protein Binding | 62 % |
| Volume of Distribution | 1.8 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Metabolized mainly by CYP3A4 and partially by CYP2D6; substrate of P-glycoprotein. Avoid strong CYP3A inhibitors/inducers (e.g., ketoconazole, rifampin). Steady state reached in ~3 days. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Dizziness, constipation, nausea, headache, QT interval prolongation
Contraindications:
Pre-existing QT prolongation, hepatic impairment, concomitant use of strong CYP3A inhibitors
Precautions:
Monitor ECG for QT interval; adjust dose in moderate renal impairment; avoid grapefruit products; caution with other QT-prolonging drugs